OverviewChartNewsTraderScreen

Soc. Generale Call 7 ATO 20.12.20.../  DE000SU2Z7Q4  /

EUWAX
31/05/2024  10:12:48 Chg.-0.001 Bid22:00:35 Ask22:00:35 Underlying Strike price Expiration date Option type
0.027EUR -3.57% -
Bid Size: -		 -
Ask Size: -		 Atos SE 7.00 EUR 20/12/2024 Call
GlobeNewswire 30/05 Groundbreaking Technology Solves Major Problem of User Lockouts During MFA Resets
GlobeNewswire 28/05 NetLogistik Wins Partner Leadership Award from Blue Yonder
GlobeNewswire 28/05 Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast...
GlobeNewswire 16/05 Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats
GlobeNewswire 15/05 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...
GlobeNewswire 15/05 Calian Reports Record Results for the Second Quarter
GlobeNewswire 13/05 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 13/05 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing
GlobeNewswire 07/05 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
GlobeNewswire 29/04 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire 15/04 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...
GlobeNewswire 11/04 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
GlobeNewswire 09/04 Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...
GlobeNewswire 01/04 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
GlobeNewswire 27/03 Calian Announces the Appointment of New President of Advanced Technologies
GlobeNewswire 25/03 Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks
GlobeNewswire 19/03 Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...
GlobeNewswire 18/03 Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
GlobeNewswire 12/03 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...
GlobeNewswire 06/03 Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...
GlobeNewswire 22/02 Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
GlobeNewswire 16/01 New report reveals that 94% of global organizations have experienced email security incidents last y...
GlobeNewswire 09/01 Atossa Therapeutics Issues Letter to Shareholders
TeleTrader 03/01 Europe opens mixed with data, business in focus
TeleTrader 03/01 Airbus to purchase Atos' cyber security unit for $1.9B